Lilly maintains deal streak with $1.2B pact for Hanmi’s GLP-2 candidate

Expanding in the metabolic space, Eli Lilly has struck a back-loaded licensing deal with South Korea’s Hanmi Pharm for a mid-stage GLP-2 agonist being trialed for short bowel syndrome.